Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.
Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
The deal will focus on Biocartis' Idylla MSI test, which provides information on a tumor's microsatellite instability status of a tumor from a single FFPE slice.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.
